Your browser doesn't support javascript.
loading
Risankizumab shows high efficacy and maintenance in improvement of response until week 52.
Mastorino, Luca; Susca, Sara; Megna, Matteo; Siliquini, Niccolò; Quaglino, Pietro; Ortoncelli, Michela; Avallone, Gianluca; Rubatto, Marco; Fabbrocini, Gabriella; Dapavo, Paolo; Ribero, Simone.
  • Mastorino L; Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
  • Susca S; Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
  • Megna M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Siliquini N; Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
  • Quaglino P; Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
  • Ortoncelli M; Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
  • Avallone G; Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
  • Rubatto M; Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
  • Fabbrocini G; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
  • Dapavo P; Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
  • Ribero S; Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
Dermatol Ther ; 35(5): e15378, 2022 05.
Article en En | MEDLINE | ID: mdl-35156278

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis / Artritis Psoriásica Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis / Artritis Psoriásica Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article